Protocol Ledger

NCT06833983 · Phase III · RECRUITING

To Evaluate the Clinical Study of GS1191-0445 Injection in the Treatment of Hemophilia A

Interventional Phase III clinical trial protocol NCT06833983 sponsored by Gritgen Therapeutics Co in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-03-31 Enrollment: 50 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06833983
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)50 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06833983
Protocol FieldVerified Registry Value
NCT IdentifierNCT06833983
Consolidated Lead SponsorGritgen Therapeutics Co
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment50 participants (ESTIMATED)
Registered Start Date2025-03-31
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT06833983
Hospital Research SiteLocationSite Profile
Anhui Provincial HospitalHefei, ChinaOpen Hospital Dossier ->
Peking Union Medical College HospitalBeijing, ChinaOpen Hospital Dossier ->
Nanfang Hospital, Southern Medical UniversityGuangzhou, ChinaOpen Hospital Dossier ->
Henan Cancer HospitalZhengzhou, ChinaOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI